These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1452308)

  • 41. Seroprevalence of hepatitis B and hepatitis C in patients with thalassemia and sickle cell anemia in a long-term follow-up.
    Ocak S; Kaya H; Cetin M; Gali E; Ozturk M
    Arch Med Res; 2006 Oct; 37(7):895-8. PubMed ID: 16971232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Frequency distribution and risk factors of hepatitis B virus and hepatitis C virus infections among thalassemia patients: a regional study.
    Shah T; Hussain W; Ali N; Sardar S; Ishaq M; Ur Rahman M; Ding L; Qayyum S; Khan I
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):248-252. PubMed ID: 30358571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment and prevention of hepatitis B and C in thalassemia.
    Mallat ME; Sharara AI
    Hemoglobin; 2009; 33 Suppl 1():S139-44. PubMed ID: 20001618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Occult HBV infection in multi transfused thalassemia patients.
    Sabat J; Dwibedi B; Dash L; Kar SK
    Indian J Pediatr; 2015 Mar; 82(3):240-4. PubMed ID: 24928107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transfusion transmitted infections in frequently transfused thalassemic children living in Fayoum Governorate, Egypt: Current prevalence and risk factors.
    Atwa ZT; Abdel Wahed WY
    J Infect Public Health; 2017; 10(6):870-874. PubMed ID: 28292647
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of markers for human immunodeficiency virus types 1 and 2, human T-lymphotropic virus type I, cytomegalovirus, and hepatitis B and C virus in multiply transfused thalassemia patients. The French Study Group On Thalassaemia.
    de Montalembert M; Costagliola DG; Lefrère JJ; Cornu G; Lombardo T; Cosentino S; Perrimond H; Girot R
    Transfusion; 1992; 32(6):509-12. PubMed ID: 1323885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disappearance after two years of HBsAg and HBsAb in multiply transfused thalassemic patients and in their relatives in Sardinia.
    Scalise G; Cuccuru G; Stangoni A; Mela G; Cutillo S; Dore A; Gioannini P
    Panminerva Med; 1979; 21(1):7-10. PubMed ID: 492747
    [No Abstract]   [Full Text] [Related]  

  • 48. Chronic hepatitis virus infection in children.
    Chang MH
    J Gastroenterol Hepatol; 1998 May; 13(5):541-8. PubMed ID: 9641657
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of infectious disease markers in multitransfused Egyptian children with thalassemia.
    Hussein E
    Ann Clin Lab Sci; 2014; 44(1):62-6. PubMed ID: 24695476
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major.
    Wonke B; Hoffbrand AV; Brown D; Dusheiko G
    J Clin Pathol; 1990 Aug; 43(8):638-40. PubMed ID: 2119395
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Prevalence of hepatitis A antibodies in polytransfused thalassemic patients].
    Mangiagli A
    Pediatr Med Chir; 1997; 19(6):437-8. PubMed ID: 9595581
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence and clinical significance of hepatitis C virus infection in Thai patients with thalassemia.
    Wanachiwanawin W; Luengrojanakul P; Sirangkapracha P; Leowattana W; Fucharoen S
    Int J Hematol; 2003 Nov; 78(4):374-8. PubMed ID: 14686498
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of hepatitis A and B infections in multiply transfused thalassaemic patients.
    Papaevangelou G; Frösner G; Economidou J; Parcha S; Roumeliotou A
    Br Med J; 1978 Mar; 1(6114):689-91. PubMed ID: 630296
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Incidence of Australia antigen (HB Ag) and its related antibody (HB Ab) in Siciliam thalassemic children treated with multiple transfusions].
    Musumeci S; Di Gregorio F; Marino S; Fischer A; Pizzarelli G
    Pediatria (Napoli); 1977 Mar; 85(1):21-33. PubMed ID: 876745
    [No Abstract]   [Full Text] [Related]  

  • 55. The dangerous outcomes of blood transfusion to thalassemia patients in Pakistan.
    Shah DA
    J Infect Public Health; 2015; 8(5):510-1. PubMed ID: 25731675
    [No Abstract]   [Full Text] [Related]  

  • 56. Australia antigen (HBsAg) in thallassemia children receiving multiple transfusions.
    Mehta KP; Patil HL; Merchant SM; Babar ST; Baxi AJ; Bapat JP
    Indian Pediatr; 1977 Jun; 14(6):455-9. PubMed ID: 604273
    [No Abstract]   [Full Text] [Related]  

  • 57. Cultural preferences and limited public resources influence the spectrum of thalassemia in Egypt.
    Adly AA; Ebeid FS
    J Pediatr Hematol Oncol; 2015 May; 37(4):281-4. PubMed ID: 25811748
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prospective study for prevalence and/or development of transfusion-transmitted infections in multiply transfused thalassemia major patients.
    Jain R; Perkins J; Johnson ST; Desai P; Khatri A; Chudgar U; Choudhury N
    Asian J Transfus Sci; 2012 Jul; 6(2):151-4. PubMed ID: 22988380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatitis B, C & D viral markers in multitransfused thalassemic children: long-term complications and present management.
    Choudhry VP; Acharya SK
    Indian J Pediatr; 1995; 62(6):655-68. PubMed ID: 10829940
    [No Abstract]   [Full Text] [Related]  

  • 60. Chronic viral hepatitis in thalassemic liver disease. A long-term study in patients with acute hepatitis with nontransfusion-dependent thalassemia minor.
    Pastore G; Tannoia N; Angarano G; Monno L; Santantonio T; Pietrapertosa A; Malcangi G; Putignano A; Schiraldi O
    Vox Sang; 1983; 44(1):14-24. PubMed ID: 6402856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.